73778-95-7Relevant articles and documents
Lead identification of benzimidazolone and azabenzimidazolone arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists
Miah, Afjal H.,Abas, Hossay,Begg, Malcolm,Marsh, Benjamin J.,O'Flynn, Daniel E.,Ford, Alison J.,Percy, Jonathan M.,Procopiou, Panayiotis A.,Richards, Steve A.,Rumley, Sally-Anne
, p. 4298 - 4311 (2014)
A knowledge-based library of 2,3-dichlorophenylsulfonyl derivatives of commercially available aryl amines was synthesised and screened as human CCR4 antagonists, in order to identify a suitable hit for the start of a lead-optimisation programme. Hits were required to be more potent than an existing indazole series, have better physicochemical properties (c log P 7.4 116 μg/mL), and be stable to acid and light. The benzimidazol-2-one core was identified as a hit suitable for further investigation. Substitution at N1 with small alkyl groups was tolerated; however, these analogues were inactive in the whole blood assay (pA2 7.4 (2.4), high LE (0.43), and solubility (152 μg/mL). In addition, 38 had human serum albumin binding of around 93% and met all the criteria for progression to lead optimisation.